Wockhardt, the Mumbai based drug maker, is said to be in ‘advanced stages of discussions’ for clinching a deal to produce Covid-19 drugs and vaccine. A formal declaration in this regard may be expected over the next two-three weeks..
The decision came as an outcome the day after Union Health Ministry finalised advance deal with Hyderabad-based vaccine manufacturer Biological-E to stockpile 30 crore coronavirus vaccine doses.
Reportedly, Wockhardt is in liaison with multiple players for technology transfer collaborations to manufacture anti-Covid vaccine, oral and nasal drugs. The medicines will be developed at a dedicated space in existing and new facilities in Maharashtra’s Waluj and Shendra, near Aurangabad.
Wockhardt is also in talks with the global vaccine manufacturers as well as the Indian government for distribution of these medications.
Also the firm has already came into a pact in India for production of an undisclosed vaccine, which may commence in October. Wockhardt chairman Habil Khorakiwala assured that the company is now well equipped to manufacture 500 million doses a year and is in talks with overseas pharma companies to get collaborations for already approved vaccines too.
“Since the relevant agreements are not yet fully finalised, the same has not been informed to the stock exchanges”, Habil added.